Background. ME1100 (arbekacin inhalational solution) is an aminoglycoside in clinical development for the treatment of patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP, respectively). Due to the increase in resistance of Staphylococcus aureus and Pseudomonas aeruginosa to many antimicrobial agents, it is important to understand the relationships between amplification of drug resistance and each of drug exposure and therapy duration. The objective of the studies described herein was to utilize the HFIM to determine the arbekacin exposure after ME1100 administration required to prevent the emergence of drug-resistant subpopulations.
Background. Differences in pharmacokinetic and pharmacodynamic parameters for obese (OB) patients compared with nonobese (NOB) patients are well known, but drug safety and efficacy when using package insert dosing remain unclear. The purpose of this study was to evaluate the clinical outcomes of cefepime (FEP) for OB patients vs. NOB patients.
Methods. This retrospective cohort included inpatient adults ≥18 years treated with FEP monotherapy for ≥72 hours between July 2015 and July 2017. Exclusion criteria were source control not achieved within 72 hours and polymicrobial infections requiring > 1 antibiotic for definitive therapy. Additional data collected were demographics, comorbid conditions, laboratory markers, site of infection, and microbiology. The primary endpoint was clinical treatment failure, defined as change in definitive therapy at >72 hours due to clinical worsening, leukocytosis (WBC > 10 × 10 9 /L) for >72 hours after treatment initiation, fever (single temperature >100.9°F) after >72 hours of treatment initiation, or readmission within 30 days due to re-infection. Secondary outcomes were 30-day inpatient all-cause mortality and 30-day readmission.
Results. One hundred fourteen subjects were included (58 OB; 56 NOB). Median (IQR) age 58 -5] (P = 0.478). Sixty-two percent OB patients vs. 46% NOB patients experienced a respiratory infection (P = 0.094); 28% OB patients vs. 39% NOB patients experienced a urinary tract infection (P = 0.185). 62% OB patients and 59% NOB patients received FEP 1g q8h (P = 0.732). Most common minimum inhibitory concentration (MIC) in both groups was 1 mg/L (74% OB vs. 83% NOB; P = 0.289). Clinical failure occurred in 52% (67% OB vs. 36% NOB; P = 0.001). OB patients more likely to need a second antibiotic (31% vs. 14%; P = 0.033) and have persistent leukocytosis (50% vs. 30%; P = 0.033). Inpatient all-cause mortality occurred in 17% (22% OB vs. 12% NOB; P = 0.164). 72% of patients were not readmitted within 30 days of discharge.
Conclusion. OB patients experienced higher treatment failure than NOB patients. Further examination is needed to assess impact of FEP dose and organism MIC on clinical failure in OB patients.
Disclosures. All authors: No reported disclosures. Background. Ceftriaxone (CRO), while highly protein bound, retains a small volume of distribution. Obese patients have larger volumes of distributions and higher clearance than nonobese patients. The effect of these differences on the pharmacokinetics and efficacy of CRO remain unclear.
Impact of Total Body Weight on Efficacy of Ceftriaxone in Obese Patients
Methods. This retrospective cohort study included adult in-patients who received CRO for ≥72 hours as definitive monotherapy from July 2015 to July 2017. Patients were excluded if there was a lack of adequate source control at 72 hours or if there was a polymicrobial infection requiring multiple antibiotics. Obesity was defined as BMI ≥30 kg/m 2 . The primary outcome was clinical treatment failure, defined as changing therapy at >72 hours due to clinical worsening, leukocytosis (WBC > 10 × 10 9 /L), fever (single temperature >100.9°F) for >72 hours, or readmission to the hospital within 30 days for re-infection. Secondary outcomes included discharge disposition and 30-day readmission.
Results. One hundred one patients were included: 39 obese patients and 62 nonobese patients. nonobese; P = 0.293). Infection sources were similar: urinary tract (54% obese vs. 52% nonobese; P = 0.827), respiratory (28% obese vs. 23% nonobese; P = 0.524), bloodstream (20% obese vs. 23% nonobese; P = 0.806). The most common causative organism was E. coli (48%). There were no differences in CRO regimen between groups (1g q24h: obese 54% vs. nonobese 69%; P = 0.115). Treatment failure occurred in 24 (61%) obese patients compared with 25(40%) nonobese patients (P = 0.038). Obese patients had delayed resolution of leukocytosis (54% vs. 29%, P = 0.013). Eight patients died (13% obese vs. 5% nonobese; P = 0.255); 82% of patients were not readmitted within 30 days.
Conclusion. Obese patients treated with ceftriaxone had higher rates of treatment failure compared with nonobese patients. While not statistically significant, there was numerically higher mortality in obese patients compared with nonobese patients. Obese patients may be slow to recover from infection when treated with CRO.
Disclosures. All authors: No reported disclosures. We found no correlation with co-administered nephrotoxic agents, vancomycin troughs, or body weight and AKI.
Conclusion. Our prospective observational study data revealed significant AKI with PTZ-V compared with CEF-V but it did not impact patient long-term outcomes. Caution with PTZ-V may be required when used in ICU settings even in patients with normal baseline CrCl.
Disclosures. J. S. Lewis II, Merck: Consultant, Consulting fee. Background. NOSO-502 is a novel, first-in-class Odilorhabdin antibiotic targeting bacterial protein translation, with potent in vitro activity against Enterobacteriaceae including strains with MDR or CRE-phenotype. The goal of this study was to determine the PK/PD characteristics of NOSO-502 using the murine thigh infection model against a diverse group of EC and KPN strains.
In vivo
Methods. Twelve strains (6 EC, 6 KPN) were utilized, including those with tetracycline or β-lactam resistance. MICs were determined by CLSI Methods. Single dose murine plasma PK of NOSO-502 was determined after administration of 7.81, 31.25, 125 and 500 mg/kg by SC route. Dose fractionation (DF) study was used to determine which PK/PD index was associated with efficacy. The relationship between each PK/ PD indices and CFU outcome data were analyzed using the sigmoid Emax (Hill) model with nonlinear regression. Treatment studies were then performed with the remaining 11 strains. Four-fold increasing NOSO-502 doses (3.91-1,000 mg/kg/6 hours SC route) were administered. Treatment data and AUC/MIC was analyzed to determine AUC/ MIC targets associated with net stasis and 1-log kill (when achieved) for all strains.
Results. MICs ranged from 1 to 4 mg/L. PK ranges for doses included: Cmax 1.5-85 mg/L, AUC 0-∞ 1.9-352 mg hour/L, T1/2 0.4-1.1 hour. DF regression analysis: AUC/MIC R 2 0.86, Cmax/MIC R 2 0.70, T > MIC R 2 0.77. Against each of the 12 strains there was dose-dependent activity and net stasis was achieved against all strains, with maximal activity of 1-2 log killing in EC and almost 3 log killing in KPN. The 24 hours stasis total and free drug PD targets are shown (table). 1-log kill targets were determined for KPN and noted at a median 24 hours fAUC/MIC of 11. 
